Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children

November 16, 2016 updated by: Novartis Pharmaceuticals

An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment

The purpose of this extension study is to assess the long-term safety and tolerability of omalizumab as an add-on therapy in Japanese pediatric patients (6 to 15 years of age) with inadequately controlled allergic asthma despite current recommended treatment by providing continued treatment with omalizumab to patients who have previously completed the core study.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

38

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Japan
      • Chiba, Japan, 266-0007
        • Novartis Investigative Site
      • Fukuoka, Japan, 811-1394
        • Novartis Investigative Site
      • Gifu, Japan, 501-1194
        • Novartis Investigative Site
    • Aichi
      • Ohbu, Aichi, Japan, 474-0031
        • Novartis Investigative Site
    • Kanagawa
      • Sagamihara-city, Kanagawa, Japan, 228-8522
        • Novartis Investigative Site
      • Yokohama, Kanagawa, Japan, 245-8575
        • Novartis Investigative Site
      • Yokohama, Kanagawa, Japan, 232-8555
        • Novartis Investigative Site
    • Mie
      • Tsu, Mie, Japan, 514-0125
        • Novartis Investigative Site
    • Nara
      • Tenri, Nara, Japan, 632-8552
        • Novartis Investigative Site
    • Osaka
      • Habikino city, Osaka, Japan, 583-8588
        • Novartis Investigative Site
    • Tochigi
      • Shimotsuka-gun, Tochigi, Japan, 321-0293
        • Novartis Investigative Site
    • Tokyo
      • Fuchu, Tokyo, Japan, 183-8561
        • Novartis Investigative Site
      • Komae, Tokyo, Japan, 201-8601
        • Novartis Investigative Site
      • Setagaya-ku, Tokyo, Japan, 158-0097
        • Novartis Investigative Site
      • Sumida-ku, Tokyo, Japan, 130-8587
        • Novartis Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 15 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients who completed the core study (IGE025B1301) and who in the investigator's clinical judgment could benefit from continuous treatment of the study drug.

Exclusion Criteria:

  • Patients who currently have diagnosed cancer, are currently being investigated for possible cancer or have any history of cancer.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are: women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; women whose partners have been sterilized by vasectomy or other means; using a highly effective method of birth control; or agreeing on total abstinence and the investigator also judges that the age, career lifestyle or sexual orientation of the patient ensures compliance.
  • With clinically significant uncontrolled systemic disease (eg: infection, hematological disease, renal, hepatic, coronary heart disease or other cardiovascular disease, cerebro-vascular, endocrinologic or gastrointestinal disease) after the treatment period of the core study.
  • Patients with a history of major protocol violations during the core study and who are considered potentially unreliable as judged by the investigator at each site.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Omalizumab
Drug: Omalizumab
omalizumab lyophilized 150 mg injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To assess the long-term safety and tolerability of omalizumab by measuring AEs, serious AEs, physical examination, medical history, laboratory assessments and vital signs
Time Frame: Every 3 months for approximately 2 years
Every 3 months for approximately 2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
To explore the efficacy of omalizumab by JPAC questionnaire; JPAC is the Japan Pediatric Asthma Control Program (JPAC)
Time Frame: Every 3 months for approximately 2 years
Every 3 months for approximately 2 years
To explore the efficacy of omalizumab by QOL questionnaire score (Quality of life questionnaires for pediatric patients with bronchial asthma and their parents or caregivers (Gifu))
Time Frame: Every 3 months for approximately 2 years
Every 3 months for approximately 2 years
To explore the efficacy of omalizumab by use of asthma long-term control medications
Time Frame: Every 3 months for approximately 2 years
Every 3 months for approximately 2 years
To explore the efficacy of omalizumab by Pulmonary function (FEV1, FVC, V(・)50, V(・)25 and FEF25-75%)
Time Frame: Every 3 months for approximately 2 years
Every 3 months for approximately 2 years
To collect the data on the number of hospitalizations, emergency room (ER) visits due to asthma
Time Frame: Every 3 months for approximately 2 years
Every 3 months for approximately 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novartis Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2011

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

April 1, 2011

First Submitted That Met QC Criteria

April 4, 2011

First Posted (Estimate)

April 5, 2011

Study Record Updates

Last Update Posted (Estimate)

November 18, 2016

Last Update Submitted That Met QC Criteria

November 16, 2016

Last Verified

November 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CIGE025B1301E1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe